How the University of North Carolina at Chapel Hill Is Enhancing RNAi Potency with Its New Technology

Why It Matters

Higher potency at lower doses expands RNAi’s therapeutic window and opens new disease areas, especially hard‑to‑target cancers. The platform’s compatibility with current delivery methods accelerates its commercial potential.

Key Takeaways

• DNA dT overhang enhances RISC loading efficiency
• Modified siRNAs show lower ED50 versus Hi2OMe controls
• Platform works across genes, including KRAS G12V mutation
• Compatible with existing lipid nanoparticle delivery systems
• Enables lower dosing, reducing toxicity risk

Pulse Analysis

RNA interference has moved from a laboratory curiosity to a validated class of medicines, yet most approved siRNA drugs are confined to liver targets because delivery and potency constraints limit their reach. Conventional chemical tweaks improve stability but can interfere with the Argonaute‑2 protein that drives mRNA cleavage, forcing developers to use higher doses that raise safety concerns. This bottleneck has spurred a wave of research aimed at refining the siRNA architecture, especially the 5′ end of the antisense strand, which dictates how efficiently the guide strand is selected by the RNA‑induced silencing complex.

UNC‑Chapel Hill’s breakthrough adds two or more deoxythymidine nucleotides to the 5′ terminus of the antisense strand, creating a “sticky” overhang that promotes rapid and accurate RISC loading. In head‑to‑head cell‑based assays targeting KRAS and MYC, the dT‑modified duplexes achieved markedly lower ED₅₀ values than the industry‑standard Hi2OMe design, translating to stronger gene knock‑down with less material. The modification is gene‑agnostic, improving potency for both wild‑type and mutant sequences such as KRAS G12V, and it integrates seamlessly with lipid‑nanoparticle or ligand‑conjugate delivery platforms already used in clinical pipelines.

The implications for biotech and pharma are significant. By delivering comparable or superior silencing at a fraction of the dose, the technology reduces the risk of off‑target effects and systemic toxicity, two major hurdles in expanding RNAi beyond hepatic diseases. Companies can now consider siRNA candidates for oncology, neurodegeneration, and other tissue‑specific indications without redesigning their entire delivery stack. As investors seek next‑generation gene‑silencing tools, UNC’s platform positions itself as a scalable, low‑risk upgrade that could accelerate the pipeline of RNAi therapeutics and reshape the competitive landscape.